ClinicalTrials.gg
CompletedNCT05341089Updated May 27, 2026Results posted

A Study of Two Different Formulations of LY3502970 in Healthy Participants

A Phase 1 interventional study of LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

The main purpose of this study is to conduct blood tests to measure how much LY3502970 is in the bloodstream when administered as two different formulations in healthy participants. The study will also evaluate the safety and tolerability of LY3502970. The study will last up to 13 weeks excluding the screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy as determined by medical evaluation
  • Participants who have a level of at least 11.4 grams per deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants
  • Participants with a body weight of at least 45 kilograms (kg) and (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²)
  • Male participants who agree to use highly effective/effective methods of and female participants not of

Exclusion criteria

Exclusion Criteria:

  • Participants who have any abnormality in the 12-lead (ECG) at screening
  • Participants who have an abnormal blood pressure, pulse rate, or both, which are deemed to be by the investigator, at screening
  • Participants who have known allergies to LY3502970, related compounds, or any components of the formulation
  • Participants who have used or intend to use over-the-counter or prescription medication including herbal medications or traditional medications within 14 days prior to dosing
  • Participants who show evidence of (HIV) infection and/or positive HIV antibodies, or both. A negative test within 6 months of screening would not need to be repeated.
  • Participants who show evidence of and/or positive hepatitis C antibody, or both. A negative test within 6 months of screening would not need to be repeated.
  • Participants who show evidence of , positive hepatitis B surface antigen, and/or positive hepatitis B core antibody, or all. A negative test within 6 months of screening would not need to be repeated.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    2 mg/4mg/8mg LY3502970 - Dose Titration Period

    Participants received escalating oral doses of LY3502970 according to the following dosing schedule: * Days 1-7: 2 milligrams (mg) once daily (QD) * Days 8-14: 4 mg QD * Days 15-21: 8 mg QD

    Drug: LY3502970

  • Experimental
    16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period

    Participants received 16 mg LY3502970 Formulation 1 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 2 orally QD from Days 29-35 in test period 2.

    Drug: LY3502970

  • Experimental
    16 mg LY3502970 (Formulation 2/Formulation 1) - Test Period

    Participants received 16 mg LY3502970 Formulation 2 orally QD from Days 22-28 in test period 1, followed by 16 mg LY3502970 Formulation 1 orally QD from Days 29-35 in test period 2.

    Drug: LY3502970

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2

    PK: Cmax of LY3502970 in Formulation 1 and Formulation 2

    Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

  2. PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2

    PK:(AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2

    Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

  3. PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2

    PK: Tmax of LY3502970 in Formulation 1 and Formulation 2

    Time frame: Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

07

Results

Posted May 27, 2026

Participant flow

Dose Titration Period
Participant flow — Dose Titration Period
Milestone2 mg/4mg/8mg LY3502970 - Dose Titration Period16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period
Started3900
Received at least one dose of ly35029703800
Completed3400
Not completed500
Withdrew: Adverse event400
Withdrew: Physician decision100
Test Period 1
Participant flow — Test Period 1
Milestone2 mg/4mg/8mg LY3502970 - Dose Titration Period16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period
Started01717
Received at least one dose of ly350297001717
Completed01716
Not completed001
Withdrew: Adverse event001
Test Period 2
Participant flow — Test Period 2
Milestone2 mg/4mg/8mg LY3502970 - Dose Titration Period16 mg LY3502970 (Formulation 1/Formulation 2) - Test Period16 mg LY3502970 (Formulation 2/Formulation 1) -Test Period
Started01716
Received at least one dose of ly350297001716
Completed01715
Not completed001
Withdrew: Withdrawal by subject001

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2

PK: Cmax of LY3502970 in Formulation 1 and Formulation 2

Time frame:
Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2
nanogram per milliliter (ng/mL)16 mg LY3502970 (Formulation 1)16 mg LY3502970 (Formulation 2)
Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 286.5 ± 4086.5 ± 43
PrimaryPK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2

PK:(AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2

Time frame:
Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
Reported as:
Geometric mean · Nanogram*hour per milliliter (ng*h/mL)
PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2
Nanogram*hour per milliliter (ng*h/mL)16 mg LY3502970 (Formulation 1)16 mg LY3502970 (Formulation 2)
PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 21260 ± 381240 ± 40
PrimaryPK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2

PK: Tmax of LY3502970 in Formulation 1 and Formulation 2

Time frame:
Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose
Reported as:
Median · Hours (h)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2
Hours (h)16 mg LY3502970 (Formulation 1)16 mg LY3502970 (Formulation 2)
PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 26.00 (4.00 to 23.92)6.00 (2.00 to 12.00)

Adverse events

Collected over From baseline until end of follow-up (up to 49 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2 mg LY3502970 - Dose Titration Period0/38 (0%)0/38 (0%)23/38 (60.5%)
4 mg LY3502970 - Dose Titration Period0/37 (0%)0/37 (0%)8/37 (21.6%)
8 mg LY3502970 - Dose Titration Period0/34 (0%)0/34 (0%)17/34 (50%)
16 mg LY3502970 (Formulation 1)0/33 (0%)0/33 (0%)24/33 (72.7%)
16 mg LY3502970 (Formulation 2)0/34 (0%)0/34 (0%)24/34 (70.6%)
Most frequent other events
Showing 10 of 16
Most frequent other events
Event2 mg LY3502970 - Dose Titration Period4 mg LY3502970 - Dose Titration Period8 mg LY3502970 - Dose Titration Period16 mg LY3502970 (Formulation 1)16 mg LY3502970 (Formulation 2)
VomitingGastrointestinal disorders13/383/376/346/334/34
Decreased appetiteMetabolism and nutrition disorders13/382/372/340/333/34
Catheter site erythemaGeneral disorders3/380/370/3410/3310/34
Catheter site bruiseGeneral disorders1/380/370/349/333/34
Abdominal distensionGastrointestinal disorders10/382/373/341/331/34
NauseaGastrointestinal disorders9/383/376/342/335/34
HeadacheNervous system disorders3/381/376/343/335/34
Catheter site painGeneral disorders0/380/371/344/334/34
Catheter site phlebitisGeneral disorders0/380/370/340/334/34
DiarrhoeaGastrointestinal disorders2/380/372/343/332/34

Baseline characteristics

All participants who received at least one dose of LY3502970.

Age, Continuous
Age, Continuous(years)2 mg/4mg/8mg LY3502970 - Dose Titration Period
Mean40.4 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)2 mg/4mg/8mg LY3502970 - Dose Titration Period
Female4
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)2 mg/4mg/8mg LY3502970 - Dose Titration Period
Hispanic or Latino0
Not Hispanic or Latino38
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2 mg/4mg/8mg LY3502970 - Dose Titration Period
American Indian or Alaska Native0
Asian38
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)2 mg/4mg/8mg LY3502970 - Dose Titration Period
Singapore38
08

Study locations

1 site
  • Lilly Centre for Clinical Pharmacology
    Singapore, 138623, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Sep 2022, 3 months.

Results were first posted in May 2026, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2022
First posted
Apr 22, 2022
StartActual
May 17, 2022
Primary completionActual
Sep 1, 2022
CompletionActual
Sep 1, 2022
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05341089
Responsible party
Sponsor
First posted
Apr 22, 2022
Start date
May 17, 2022
Primary completion
Sep 1, 2022
Completion
Sep 1, 2022
Results posted
May 27, 2026
Last update
May 27, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orforglipron

Start the discussion